Evidence map›Paper›PMID 30105253›Full record

SynthesisBioMed research international2018

Prognostic Significance of P16

Jiayi Zhang, Hengcheng Zhang, Yanyan Xiu, Hong Cheng, Min Gu, Ninghong Song

Open access · hybridAbstract readMeta-Analysis
In one paragraph

Synthesis in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jiayi Zhang *Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-8579-7754
Hengcheng Zhang *Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-2562-1247
Yanyan Xiu *Department of Dermatology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-8278-2477
Hong ChengDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-6341-541X
Min GuDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-0589-7246
Ninghong SongDepartment of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0003-4963-4912
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, P16

methodsA systematic search was performed in PubMed, Embase, and Web of Science to identify all relevant articles up to May 25, 2017. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of included studies were pooled to estimate the prognostic value. Trial sequential analysis (TSA) was performed to assess the quantity and strength of survival evidence.

resultsFive retrospective studies consisting of 323 cases were finally included. We found that P16

conclusionsP16

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16HumansMalePenile NeoplasmsPrognosisRetrospective StudiesBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16

Identifiers

PMID30105253
PMCPMC6076906
OpenAlexW2884963873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.